The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
In this double clinical trial 132 patient with the history of DME (Diabetic Macular Edema) to
receive intravitreous bevacizumab at a dose of 1.25mg (44 patient) , ziv-aflibercept at dose
of 1.25 mg (44 patient) , ziv-aflibercept at dose of 2.5 mg (44 patient) .
The study drugs were administered as often as every 4 weeks for 3 months.monitoring of
best-corrected visual acuity, CST ( Central Subfield Thickness) by OCT (Optical coherence
tomography) was done from base line ,4 weeks, 8weeks after injection.